Deferoxamine

Iron Chelator — VARIOUS

Key facts

Deferoxamine is an ofp drug in the Iron Chelator class catalogued in DrugCentral. It was first approved by the FDA in 1968. Its mechanism of action is classified as Iron Chelating Activity. DrugCentral lists 4 molecular targets, including KDM4A, DOHH and HIF1A. Recorded indications include Chronic Iron Overload and Poisoning by iron AND/OR its compounds.

• Approval status: ofp (first approved 1968 by the FDA).
• Drug class: Iron Chelator.
• Mechanism of action: Iron Chelating Activity.
• Molecular targets: KDM4A, DOHH, HIF1A and TET2 (4 listed in DrugCentral).
• Indications: Chronic Iron Overload and Poisoning by iron AND/OR its compounds.
• ATC code: V03AC01 (Iron chelating agents).
• Molecular formula: C25H48N6O8; molecular weight 560.69 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Chronic Iron Overload
• Poisoning by iron AND/OR its compounds

Mechanism & targets

• Mechanism of action (MoA): Iron Chelating Activity
• Established pharmacologic class: Iron Chelator

Molecular targets (4)

Target	Gene	Action	Activity
Lysine-specific demethylase 4A	KDM4A	unknown	IC50 5.49
Deoxyhypusine hydroxylase	DOHH	unknown	IC50 5.30
Hypoxia-inducible factor 1-alpha	HIF1A	unknown	EC50 4.75
Methylcytosine dioxygenase TET2	TET2	unknown	IC50 4.34

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1968-04-01	FDA	—	NOVARTIS

ATC classification

ATC code	Therapeutic hierarchy
V03AC01	VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Iron chelating agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Serum ferritin increased	443.6
Fundoscopy abnormal	131.4
Mucormycosis	87.4
Iron overload	86.3
Laryngitis fungal	79.0
Sickle cell anaemia with crisis	78.5
Liver iron concentration increased	69.5
Visual acuity reduced	67.0
Haemoglobin decreased	66.4
Blood iron increased	60.2
Blood creatinine increased	59.3
Haemochromatosis	47.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Deferoxamine is on its molecule page.

• Molecular formula: C₂₅H₄₈N₆O₈
• Molecular weight: 560.69 g/mol
• CAS number: 70-51-9
• InChIKey: UBQYURCVBFRUQT-UHFFFAOYSA-N
• PubChem CID: 2973

CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Deferoxamine used for?

DrugCentral lists the following indications for Deferoxamine: Chronic Iron Overload and Poisoning by iron AND/OR its compounds.

How does Deferoxamine work?

Deferoxamine is classified as Iron Chelating Activity; its molecular targets in DrugCentral include KDM4A, DOHH, HIF1A and TET2.

When was Deferoxamine first approved?

Deferoxamine was first approved by the FDA in 1968.

What drug class does Deferoxamine belong to?

Deferoxamine is in the Iron Chelator class.

What is the chemical formula of Deferoxamine?

Deferoxamine has the molecular formula C25H48N6O8 and a molecular weight of 560.69 g/mol.

Sources

• DrugCentral drug card 792 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1234 — compound record and bioactivity
• PubChem CID 2973 — chemical identifiers
• DrugBank DB00746 — drug record
• FDA UNII J06Y7MXW4D — substance identity
• DailyMed: FDA labels for Deferoxamine — current prescribing information (label search)
• UniProt O75164 (KDM4A) — target protein
• UniProt Q9BU89 (DOHH) — target protein
• UniProt Q16665 (HIF1A) — target protein
• UniProt Q6N021 (TET2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.